Harbor Capital Advisors Inc. Sells 49,302 Shares of Elanco Animal Health Incorporated $ELAN

Harbor Capital Advisors Inc. cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 32.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 103,761 shares of the company’s stock after selling 49,302 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Elanco Animal Health were worth $2,348,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SJS Investment Consulting Inc. lifted its stake in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Huntington National Bank grew its stake in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp lifted its stake in shares of Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after acquiring an additional 2,807 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the topic of a number of research reports. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. JPMorgan Chase & Co. increased their target price on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. KeyCorp lifted their price target on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Barclays assumed coverage on Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and an average target price of $27.67.

Elanco Animal Health Trading Up 0.1%

NYSE ELAN opened at $23.11 on Friday. The firm has a market capitalization of $11.49 billion, a PE ratio of -48.14, a price-to-earnings-growth ratio of 2.94 and a beta of 1.88. The business’s 50-day moving average price is $24.56 and its two-hundred day moving average price is $22.82. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm’s revenue was up 12.2% compared to the same quarter last year. During the same period last year, the company earned $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.